REGN

Business Context and Reporting Period

Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: Regeneron is a biopharmaceutical company focused on discovering and developing products for serious medical conditions. The company has no commercial products approved for sale and has incurred cumulative losses since inception. Its primary development programs include the IL-1 Trap (rilonacept) for inflammatory diseases, the VEGF Trap for oncology (in collaboration with sanofi-aventis), and the VEGF Trap-Eye for eye diseases (in collaboration with Bayer HealthCare for global development outside the U.S.).

Key Financial Metrics

Note: The company reported a net loss for the year. Margins are not applicable as the company has no product sales revenue.

Material Changes Versus Prior Period

• Revenue Decline: Total revenue decreased by 4.2% to $63.4 million. This was driven by the expiration of the contract manufacturing agreement with Merck in October 2006 and the completion of the Procter & Gamble collaboration in mid-2005. Contract manufacturing revenue dropped to $12.3 million from $13.7 million.
• Increased Net Loss: Net loss widened to $102.3 million from $95.4 million, primarily due to higher operating expenses relative to revenue, despite a reduction in R&D spend.
• Stronger Liquidity: Cash and marketable securities increased significantly to $522.9 million (from $316.7 million) due to a $75.0 million up-front payment from Bayer, a $25.0 million payment from sanofi-aventis, and $174.6 million in net proceeds from a November 2006 public stock offering.
• Deferred Revenue: Deferred revenue increased by $60.8 million, largely due to the $75.0 million Bayer up-front payment which is recognized over time.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• IL-1 Trap: Positive Phase 3 data was announced for Cryopyrin-Associated Periodic Syndromes (CAPS). A Biologics License Application (BLA) is planned for submission to the FDA in the second quarter of 2007.
• VEGF Trap-Eye: Phase 2 trials in wet AMD are ongoing. A Phase 3 trial is planned to begin in the second half of 2007. The collaboration with Bayer includes potential milestones totaling up to $245 million ($110M development/regulatory + $135M sales).
• VEGF Trap (Oncology): Sanofi-aventis plans to initiate Phase 3 trials in 2007 for various cancers. A registration filing is possible in 2008.
• Capital Resources: Management believes existing capital resources will meet operating needs through at least early 2010, excluding the $200 million convertible notes maturing in October 2008.

Risks and Contingencies

• Regulatory Approval: No products are currently approved. Failure to obtain FDA approval for the IL-1 Trap or VEGF Trap candidates would severely harm the business.
• Collaboration Dependence: The company relies heavily on sanofi-aventis for VEGF Trap oncology development and Bayer for VEGF Trap-Eye commercialization outside the U.S. Termination of these agreements would be materially adverse.
• Debt Obligations: The company has $200 million in convertible senior subordinated notes maturing in 2008. Failure to generate cash flow or refinance could impair operations.
• Competition: Significant competition exists in oncology (e.g., Avastin) and eye diseases (e.g., Lucentis, Macugen), which may impact market acceptance and pricing.

Investor Verification Checklist

• BLA Submission: Verify the timing and acceptance of the IL-1 Trap Biologics License Application for CAPS in Q2 2007.
• Cash Burn Rate: Monitor quarterly cash usage to confirm the runway extends to early 2010 as projected.
• Collaboration Milestones: Track progress toward Phase 3 initiation for VEGF Trap-Eye and VEGF Trap oncology to trigger potential milestone payments.
• Debt Maturity: Assess refinancing options or conversion activity for the $200 million convertible notes due in October 2008.
• Revenue Recognition: Review the amortization schedule for the $75 million Bayer and $25 million sanofi-aventis up-front payments included in deferred revenue.